Your digital copy of AccessPoint is just one step away! Please share a bit of information so we can ensure you receive future issues of AccessPoint and other content from Real-World Insights (if you wish). By filling out this form, you will have immediate access to the full AccessPoint PDF.
Download Publication
How machines learn in healthcare
Louise Parmenter
Thanks for reading! Please answer the following survey questions:
Digital health – patients’ use of mobile devices, wearables and connected virtual assistants to deliver health – is becoming integrated into virtually every aspect of healthcare. Innovative applications relevant to the pharmaceutical industry include identifying patients for therapy, enhancing the value and outcomes of treatment, engaging patients and tracking disease severity in clinical care and trial settings. Adoption of, and investment in, these technologies has now scaled to the point that pharmaceutical companies are developing and pursuing comprehensive digital health strategies. A foundational factor in drawing insights from the data derived through digital health channels is data connectivity. Linking data alone is not enough. By using real-world data methodologies, we can ensure that digital-health data produce reliable and unbiased evidence, and we can trigger changes in care management that ultimately enhance patient outcomes.
Next Generation Site Identification – From Theory to Practice
RETHINKING YOUR EVIDENCE SPEND
Arun Parekkat
No
Berlin, Germany
News
& events
Baltimore MA,
USA
Las Vegas NV, USA
Spotlight
on alzheimer’s disease (AD)
Connecting
the digital dots
view full infographic
by Marla Kessler
Matthaeus Rimpler
Kenneth Park
Glasgow, UK
Challenges in outreach efforts required for pAD and preclinical AD subjects and for more advanced subjects
Alexandra Palmer
Read
Article
Help develop trial-ready cohort by validation and use of pre-screening centers
Penny Randall
Laurence H. Keller
Major resourcing requirements in terms of equipment and staff
Nigel Rulewski
England’s National Health Service (NHS) Cancer Vanguard leads the development of new care models that will be used as an inspiration to the rest of the country’s healthcare system. As part of its mission in setting the direction for cancer care in the U.K., the Cancer Vanguard, which is revered around the world for its cancer treatment, sought to identify opportunities for optimizing care pathways for colorectal cancer (CRC) and improving the patient experience. In collaboration with Merck, a long-term partner in Colorectal Cancer (CRC) research and treatment, and uMotif, a patient data-capture platform, IQVIA proposed a first-of-its-kind solution for analyzing and visualizing care pathways.
6-8 November 2017
failure rate
Susan Tansey
Luke Dunlap
Andrea Spannheimer
DIA
Thanks for reading! Please answer the following survey questions:
I learned something new as a result of reading this article
This article contains useful information that will help me in my work.
I learned something new as a result of reading this article
RWE Value Drivers – Strategy to Execution
Optimizing patient care pathways
news
and events
New & Events
No
YES
YES
Download Publication
COMPETITION
This article contains useful information that will help me in my work.
Develop predictive algorithms to identify undiagnosed MCI patients (that go on to develop AD) through Dx and EMR data
Download Publication
human science improving outcomes
Download Publication
I learned something new as a result of reading this article
Payer
engagement
No
Cynthia L. Verst
Satisfaction with medication – capturing the patient perspective
DIA
The pace of innovation in new anti-cancer medicines is unprecedented. Advances in oncology diagnostics and therapies are transforming standards of care and significantly improving outcomes for patients. IQVIA plays an important role by supporting clinical research and observational studies, and providing access to high-quality healthcare data to enable real-world insights.
Many of these therapy/therapeutic innovations were the focus of the 2017 European Society for Medical Oncology (ESMO) Congress in Madrid, where IQVIA teams joined more than 20,000 clinicians and industry researchers in sharing knowledge about cancer research and practice.
Given the importance of the ESMO congress to the European medical oncology community, it was here that the Collaboration for Oncology Data in Europe (CODE) was launched. CODE is a groundbreaking new initiative aiming to significantly expand knowledge of anti-cancer medicines use in Europe via a dedicated Oncology Data Network (ODN). Led by IQVIA, the initiative has the support of leading biopharmaceutical companies AstraZeneca, Bristol-Myers Squibb, Eli Lilly & Co, Merck KGaA (Darmstadt, Germany) and Pfizer.
Ashley Woolmore, CODE Lead, Vice President, Real-World Insights and Head of European Data and Evidence Networks, sat down with AccessPoint to discuss the launch of CODE at ESMO, and to share his thoughts on how this innovative platform will support healthcare systems in providing financially sustainable patient care across the region.
Machine learning is transforming every facet of healthcare, as computer systems are being taught how to use Big Data to derive insights and support decision making. In this respect, teaching a computer, no less than teaching a child, is to “shape the future.” Educating a computer is a surprisingly labor-intensive process, requiring massive amounts of data, a nuanced understanding of every data element from every data source, years of trial and error, and extensive domain expertise. The key differentiator in machine learning is not the specific technology and science applied; it is in the volume and quality of the instructional material and the knowledge of the instructor.
Develop new diagnostics/screening tools for amyloid or AD via a blood test
I would recommend this article to one of my colleagues
A light touch in long-term follow-up studies
in this issue
No
YES
I would recommend this article to one of my colleagues
A light touch in long-term follow-up studies
Ana Maria Rodriguez
I learned something new as a result of reading this article
Read
Article
Download Publication
YES
80% screen failure rates in Prodomal AD
90% screen failure rates in Pre-Clinical AD
YES
Read
Article
Emile Schokker
21-24 April 2018
learn more
Broaden AD site base by increasing the number of sites ready for selection to perform AD trials
News, views and insights from leading international RWE experts
I learned something new as a result of reading this article
IQVIA Institute Research Forum
“Together with our clients, we are investing in – and committing to – advancing human health...
to rising to the challenge, to be more precise.”
This article contains useful information that will help me in my work.
No
new applications
of human Data
No
This article contains useful information that will help me in my work.
No
I would recommend this article to one of my colleagues
No
YES
31 Oct - 2 Nov 2017
Alison Bourke
Jaime Thompson
Rob Kotchie
Barbara Arone
Ali Ashrafzadeh
David Cameron
John J. Doyle
Ben Hughes
Joan L. Drucker
23-25 January 2018
YES
advances in data science
Hilary F. Armstong
World Biosimilar
Nicola Hall
Stephen Jowett
Adam Collier
Jennifer Christian
Brian Kelly
ICPE
RECAP
17-19 April 2018
Nancy Dreyer
Marla Kessler
Sydney Clark
Erica Caveney
Eric Gemmen
Natalia Balko Kotchie
Edward E. Philpot
Andrei Stoica
BIO Europe
Orlando FL, USA
11-12 May 2018
Murray Aitken
Alan Metz
Jon Resnick
Barcelona, Spain
Advances in
Data science
Designs must carefully consider
YES
of 244 agents tested for efficacy in slowing AD progression (2002-2013)
Jonathan A. Morris
This article contains useful information that will help me in my work.
Payer
engagement
Download Publication
17-18 November 2017
Results of Model-Back Test
YES
YES
new application of human data
YES
Download Publication
In May, IQVIA hosted its second annual research forum showcasing how academics and policy makers are using IQVIA real-world data to answer public health questions and inform policy debates.
Real-world data (RWD) has become a critical ingredient in demonstrating effective real-world evidence in healthcare. Incorporating data from electronic health records (EHRs), patient registries, social media and other RWD sources helps manufacturers, payers and providers drive greater value and improved patient outcomes across the healthcare spectrum. “This data isn’t only valuable to drug developers, payers and providers,” said Alison Bourke, Scientific Director at the Center for Advanced Evidence Generation at IQVIA, and President-Elect of the International Society for Pharmacoepidemiology (ISPE). “Academic researchers and public policy experts are increasingly using real-world data to address public health issues and shape treatment guidelines,” she said. In May of this year, IQVIA held its second annual research forum to showcase some of the groundbreaking studies that academics, researchers and policy makers are conducting with IQVIA data. More than 20 experts gave presentations at the two-day event, sharing details about their findings, and discussing the powerful impact that real-world data and analytics are having on public health research.
YES
Showcasing expertise and insights on RWD’s impact on safety and efficacy studies
I would recommend this article to one of my colleagues
read more
From jon resnick
No
YES
Volume 7 • Issue 14 • NOVEMBER 2017
No
Thanks for reading! Please answer the following survey questions:
Use evidence-based metrics to determine the highest potential sites
Read
Article
YES
Thanks for reading! Please answer the following survey questions:
CMSS
Thanks for reading! Please answer the following survey questions:
YES
Fez Hussain
President
Real-World Insights
jon.resnick@iqvia.com
CMSS
No
One foundational component of patient centricity is gathering feedback from patients on their experience and satisfaction with treatment. Although pharmaceutical manufacturers are generally eager to use patient reported outcomes (PRO) data, there is a concern that PROs will not be accepted by regulators or payers. The path toward such acceptance involves calibrating and verifying strong tools that can instill confidence in PRO measures. Although numerous disease-specific measures of patients’ Treatment Satisfaction with Medication (TS-M) have been cited in literature, less attention has been paid to developing a general measure of TS-M. This article highlights the importance of measuring treatment satisfaction in order to improve medication adherence and, ultimately, health outcomes.
This article contains useful information that will help me in my work.
Human Science
Improving
outcomes
YES
No
No
RETHINKING YOUR EVIDENCE SPEND
The IQVIA Real-World Insights (RWI) team brings together unrivaled experience and therapy area expertise from life sciences, consulting, government and academia. With proven expertise in all key therapy areas, as well as a range of global markets, we have a track record of helping clients capture opportunity and embrace innovation in an increasingly complex pharmaceutical landscape.
No
No
I would recommend this article to one of my colleagues
No
by Marla Kessler, Murray Aitken, Alan Metz and Jon Resnick
No
Atlanta GA, USA
I would recommend this article to one of my colleagues
Next generation site identification- from theory to practice
read this article
ISPE
This is a special AccessPoint issue for us. It is our first as IQVIA.™ Much more than a new name, we are excited to be the world’s first Human Data Science company. And I am proud to introduce – and demonstrate – Human Data Science, using data science, healthcare expertise and human data together to better measure and improve health decisions and outcomes. In its component parts, Human Data Science did not start today. As you’ll see in this issue, it’s very much already in action. Now, it’s time to bring it together.
High screen failure rates + competing trials at many of the same global sites
advances in data science
new applications of human data
Thanks for reading! Please answer the following survey questions:
I learned something new as a result of reading this article
YES
by NATALIA BALKO Kotchie, Luke Dunlap,
David Cameron, CYNTHIA Verst
We demonstrate how digital health technologies, machine learning with real-world data, and responsive, predictive modeling accelerate everything from clinical trial recruitment to the association of patient satisfaction to clinical outcomes.
Our article on How Machines Learn reveals that teaching machines about healthcare isn’t that different from teaching humans. The more data we see, the more we can use, and the more accurate healthcare becomes. But it all comes down to human expertise, intellect and, yes, even creativity.
Case studies reflect the real opportunity for patient-reported outcomes and real-world data to transform clinical trials. Improve satisfaction and adherence. Elevate the patient experience. And we move closer to understanding that real-world evidence makes developing and delivering precision medicine more precise.
We uncover a company-wide opportunity to rethink how companies allocate resources for post market studies. How to adopt new methods and approach design differently. And how to leverage data to its fullest potential.
Thanks for reading! Please answer the following survey questions:
How machines learn in healthcare
Read
Article
9-12 December 2017
read this article
BA
I would recommend this article to one of my colleagues
YES
The novel application of real-world data, statistical analysis, machine learning and predictive modeling has the potential to improve site identification for clinical trials – a process that still relies heavily on key opinion leaders (KOLs), historical experience and assumptions. There are ample statistics that emphasize how inefficient the traditional process is, and we are now gathering data points to demonstrate the degree of improvement that can be realized with the next generation approach. The following use cases quantify how these resources are accelerating site identification, improving patient enrollment rates and saving millions in operational costs per study.
by Ana Maria Rodriguez, ERIC GEMMeN,
ALEXANDRA PALMER, Louise Parmenter
No
Factors Influencing Treatment Satisfaction
I would recommend this article to one of my colleagues
No
by Nancy Dreyer, Emile Schokker, Matthaeus Rimpler, Barbara Isquith Arone
MD, MBA
This article contains useful information that will help me in my work.
YES
Thanks for reading! Please answer the following survey questions:
YES
Read
Article
YES
1
YES
We have spent the past year bringing Quintiles and IMS Health together. We knew the potential was greater than two companies merging. We knew we were creating something new.
We have emerged as IQVIA, The Human Data Science Company.™
Together with our clients, we are investing in – and committing to – advancing human health... to rising to the challenge, to be more precise. To embracing new technologies and methodologies. We are energized by how Human Data Science will accelerate our collective vision for the future.
I hope you enjoy this issue of AccessPoint, and are inspired by the potential, and the reality, of Human Data Science to drive healthcare forward.
meet us at these events
No
Download Publication
new application of human data
Toronto, Canada
MD
Download Publication
This article contains useful information that will help me in my work.
Economic consequences
of screen failures
MBA
Clinical and Commercial Applications of Digital Health
I learned something new as a result of reading this article
IQVIA shapes public health discourse at Research Forum
No
Download Publication
Download Publication
HUMAN
SCIENCE IMPROVING OUTCOMES
ISPOR
MBA
Clearer lines of communication with payers
AD clinical trial challenges
HIMSS
For disease modification trials is very high due to competing trials + geographical access to the 3 amyloid PET ligands
ISPOR
Real-World Evidence Europe
YES
BA, MA
by Arun Parekkat, Stephen Jowett
by John J. Doyle, HILARY F. ARMSTRONG
Connecting the digital dots
No
md
STUDY POPULATION
MD
MBA, MSC
Real-world data (RWD) is playing an increasingly important role in proving the safety and efficacy of new and existing treatments. These data sets, applied to the right expertise and methodologies, are being used to support label claims, to identify trends among targeted patient populations, and to demonstrate real-world results often faster and at a lower cost than through clinical studies.
IQVIA has been a leader in this space, developing a new world of innovative methodologies and study designs that enable faster and deeper insights into epidemiology, drug safety, risk and comparative safety and effectiveness. In August, we had a chance to showcase our expertise at the International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE) in Montreal. ICPE is an annual event sponsored by the International Society for Pharmacoepidemiology (ISPE) which is dedicated to advancing global public health by providing industry professionals with a forum for sharing ideas and innovations about pharmacovigilance, therapeutic risk management and related research.
“It is a fantastic forum to exchange scientific reviews, and to network with colleagues and customers,” said Alison Bourke, Scientific Director at the Center for Advanced Evidence Generation at IQVIA, and the current president-elect of ISPE. This year’s event had a huge turnout, with an estimated 1,500 experts attending, despite a last minute venue change,” she said.
Each year conference topics are developed organically based on the interests of the ISPE member community. This year much of the content was focused on the future, and how pharmacoepidemiology is evolving to meet the needs of more specific patient populations, said Nancy Dreyer, Global Chief of Scientific Affairs, Real-World Insights, IQVIA.
by Nancy Dreyer, Jennifer Christian
Read
Article
No
Read
Article
No
Burden for participants & sites
Process for amyloid disclosure
Level of staffing needed to handle
high screening throughout
No
5-9 March 2018
MD
With increasing demand for real-world evidence (RWE), sponsors are looking for more options to manage costs, serve multiple stakeholders, accelerate evidence development and increase the usability of study results. This article shows how one sponsor was able to rethink its robust Phase IV portfolio to find up to 40 percent cost savings for trials by using more innovative study designs. The results suggest that even industry leaders can benefit from additional expertise in the application of RWE.
PHD
Innovative approaches to improve AD clinical trials
Berlin, Germany
Optimizing patient care pathways
PHD, MSc, PT
RESOURCES
BA
MD, MBA
Download Publication
YES
Basel, Switzerland
13-15 November 2017
No
New & Events
I learned something new as a result of reading this article
Download Publication
No
YES
One foundational component of patient centricity is gathering feedback from patients on their experience and satisfaction with treatment. Although pharmaceutical manufacturers are generally eager to use patient reported outcomes (PRO) data, there is a concern that PROs will not be accepted by regulators or payers. The path toward such acceptance involves calibrating and verifying strong tools that can instill confidence in PRO measures. Although numerous disease-specific measures of patients’ Treatment Satisfaction with Medication (TS-M) have been cited in literature, less attention has been paid to developing a general measure of TS-M. This article highlights the importance of measuring treatment satisfaction in order to improve medication adherence and, ultimately, health outcomes.
I would recommend this article to one of my colleagues
YES
No
Thanks for reading! Please answer the following survey questions:
No
This article contains useful information that will help me in my work.
Read
Article
Ground-breaking new collaboration led by IQVIA launched at ESMO
I would recommend this article to one of my colleagues
human science improving outcomes
I would recommend this article to one of my colleagues
I learned something new as a result of reading this article
Read
Article
Arlington VA, USA
No
The predominate approach to assessing the long-term safety and effectiveness of marketed products has been to undertake extension studies that rely heavily on investigators to collect objective data on endpoints of interest, often over long periods of time. However, this is not necessarily required and can cost tens of millions of dollars. Instead, there are alternative, much more cost-effective designs that minimize clinicians’ involvement while satisfying multi-stakeholder needs. We have developed a lighter-touch approach that extends late-phase clinical trials by inviting patients into a non-interventional, follow-on study, sometimes referred to as a “rollover” study. In these studies, patients report notable health events, which later can be verified and validated, as appropriate. This direct-to-patient follow-up instills the “voice of the patient;” meets the needs of regulators, health technology assessment (HTA) bodies, physicians and patients; and is far more efficient than traditional approaches.
This article contains useful information that will help me in my work.
Thanks for reading! Please answer the following survey questions:
recruitment
The Rise of Human Data Science
in the Real World
12-15 February 2018
Humans and Machines Work in Tandem from Data Processing to Advanced Analytics
Heralding
the Era
of human
data science
No
Thanks for reading! Please answer the following survey questions:
ASH
No
YES
“This is the time to start discussing Human Data Science. While the underlying concepts have been evolving, they have been kept distinct to the point of missing the real opportunity “
YES
YES
Jon Resnick
YES
Expertise
In depth
No
Endpoints Measured from Randomization in a Clinical Trial Through to a Light-Touch Observational Follow-up Study
YES
YES
I learned something new as a result of reading this article
Read
Article
Satisfaction with medication – capturing the patient perspective
YES
24-25 April 2018
PHD, MBA, MRES, MSC
PharmD, MS
MD
MD, MBA, MS
Dr.PH, MPH
Basel
Switzerland
MD, FACC
MD
MBA
MBChB, MRCP
MA
MCOM, MBA
This article contains useful information that will help me in my work.
MD
Washington DC, USA
PHD, MPH, FISPE, FDIA
MA, PHD
MCHEM
MSC, MRPHARM.S, FISPE
esmo
recap
MS
MPhil
MBA
md
advances in data science
99.6%
$29,100/Prodromal Patient
$33,600/Pre-Clinical Patient
I learned something new as a result of reading this article
PROTOCOL DESIGN
by Andrei Stoica
19-23 May 2018
World Orphan Drug Congress
MD
M.CHEM, MSC
PHARM.D, MPH, PHD, FISPE
Chicago IL, USA
SCOPE
4-8 November 2017
MS
BSc, MSc, PHD
MBA
MS
MPH
The IQVIA and E360 names and logos, as well as any other IQVIA service or product names or logos are the registered trademarks or trademarks of IQVIA. All third party trademarks are the properties of their respective owners and are used for purposes of identification only.
Copyright © 2017 IQVIA. All rights reserved. PB.0008-1-11.2017